Evaluation of a 3D osteosarcoma model: Experimental studies and mathematical modelling of drug response Original scientific paper
Article Sidebar
Main Article Content
Abstract
Osteosarcoma remains a significant clinical challenge, with poor outcomes in metastatic cases and slow progress in the development of novel therapies. In this work, a previously developed 3D osteosarcoma model, comprising bone-mimicking macroporous alginate scaffolds with hydroxyapatite particles and a perfusion bioreactor, was evaluated as a tool for anticancer drug testing. Murine osteosarcoma cells (K7M2-wt) were seeded onto the scaffolds (15×10⁶ cells per cm³) and cultured statically for 1 day. In two experimental series, scaffolds were then exposed to doxorubicin (1 µg cm-3) under perfusion for 1 or 3 days (40 µm s-1 superficial velocity), modelling post-resection conditions with predominantly individual or loosely aggregated cells. In two additional series, the same treatments were applied after 7 days of perfusion, when compact spheroids had formed, mimicking established tumours. Histological analysis and MTT assay were used to assess cell morphology and metabolic activity. Short-term treatment had negligible effects, while prolonged exposure significantly reduced metabolic activity of individual cells, but spheroid-like structures exhibited increased doxorubicin resistance. To rationalize the results from the first two series, a mathematical model was developed describing drug transport, intracellular accumulation, cell proliferation, and cell death. The model captured the initial treatment phase, but overestimated the effect of prolonged treatment, suggesting additional resistance mechanisms. Overall, the results demonstrate the potential of this 3D model for anticancer drug evaluation.
Article Details
Issue
Section
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
Authors grant to the Publisher the following rights to the manuscript, including any supplemental material, and any parts, extracts or elements thereof:
- the right to reproduce and distribute the Manuscript in printed form, including print-on-demand;
- the right to produce prepublications, reprints, and special editions of the Manuscript;
- the right to translate the Manuscript into other languages;
- the right to reproduce the Manuscript using photomechanical or similar means including, but not limited to photocopy, and the right to distribute these reproductions;
- the right to reproduce and distribute the Manuscript electronically or optically on any and all data carriers or storage media – especially in machine readable/digitalized form on data carriers such as hard drive, CD-Rom, DVD, Blu-ray Disc (BD), Mini-Disk, data tape – and the right to reproduce and distribute the Article via these data carriers;
- the right to store the Manuscript in databases, including online databases, and the right of transmission of the Manuscript in all technical systems and modes;
- the right to make the Manuscript available to the public or to closed user groups on individual demand, for use on monitors or other readers (including e-books), and in printable form for the user, either via the internet, other online services, or via internal or external networks.
How to Cite
Funding data
-
Science Fund of the Republic of Serbia
Grant numbers 7503 -
Ministarstvo Prosvete, Nauke i Tehnološkog Razvoja
Grant numbers 451-03-34/2026-03/200135;451-03-34/2026-03/200110)
References
[1] Hosseini H, Heydari S, Hushmandi K, Daneshi S, Raesi R. Bone tumors: a systematic review of prevalence, risk determinants, and survival patterns. BMC Cancer. 2025; 25(1): 321. https://doi.org/10.1186/s12885-025-13720-0
[2] Cole S, Gianferante DM, Zhu B, Mirabello L. Osteosarcoma: A Surveillance, Epidemiology, and End Results program‐based analysis from 1975 to 2017. Cancer. 2022; 128(11): 2107–18. https://doi.org/10.1002/cncr.34163
[3] Misaghi A, Goldin A, Awad M, Kulidjian AA. Osteosarcoma: a comprehensive review. SICOT J. 2018; 4: 12. https://doi.org/10.1051/sicotj/2017028
[4] Zhang Y, Yang J, Zhao N, Wang C, Kamar S, Zhou Y, He Z, Yang J, Sun B, Shi X, Han L, Yang Z. Progress in the chemotherapeutic treatment of osteosarcoma (Review). Oncol Lett. 2018. https://doi.org/10.3892/ol.2018.9434
[5] Lieu CH, Tan A-C, Leong S, Diamond JR, Eckhardt SG. From bench to bedside: lessons learned in translating preclinical studies in cancer drug development. J Natl Cancer Inst. 2013; 105(19): 1441–56. https://doi.org/10.1093/jnci/djt209
[6] Pu F, Guo H, Shi D, Chen F, Peng Y, Huang X, Liu J, Zhang Z, Shao Z. The generation and use of animal models of osteosarcoma in cancer research. Genes Dis. 2024; 11(2): 664–74. https://doi.org/10.1016/j.gendis.2022.12.021
[7] Esposito A, Ferraresi A, Vallino L, Garavaglia B, Dhanasekaran DN, Isidoro C. Three-Dimensional In Vitro Cell Cultures as a Feasible and Promising Alternative to Two-Dimensional and Animal Models in Cancer Research. Int J Biol Sci. 2024; 20(13): 5293–311. https://doi.org/10.7150/ijbs.96469
[8] Baek N, Seo OW, Kim M, Hulme J, An SSA. Monitoring the effects of doxorubicin on 3D-spheroid tumor cells in real-time. Onco Targets Ther. 2016; 9: 7207–18. https://doi.org/10.2147/OTT.S112566
[9] Wan X, Li Z, Ye H, Cui Z. Three-dimensional perfused tumour spheroid model for anti-cancer drug screening. Biotechnol Lett. 2016; 38(8): 1389–95. https://doi.org/10.1007/s10529-016-2035-1
[10] Banicevic I, Milosevic M, Petrovic J, Milivojevic M, Gasik M, Stojkovska J, Obradovic B. Macroporous alginate scaffolds with calcium phosphate filler as a 3D in vitro microenvironment supporting bone cancer cells. International Journal of Polymeric Materials and Polymeric Biomaterials. 2026; 75(7): 820–34. https://doi.org/10.1080/00914037.2025.2608101
[11] Lin H, Yeh Y. Porous alginate/hydroxyapatite composite scaffolds for bone tissue engineering: Preparation, characterization, and in vitro studies. J Biomed Mater Res B Appl Biomater. 2004; 71B(1): 52–65. https://doi.org/10.1002/jbm.b.30065
[12] Iglesias-Mejuto A, García-González CA. 3D-printed alginate-hydroxyapatite aerogel scaffolds for bone tissue engineering. Materials Science and Engineering: C. 2021; 131: 112525. https://doi.org/10.1016/j.msec.2021.112525
[13] Bose S, Roy M, Bandyopadhyay A. Recent advances in bone tissue engineering scaffolds. Trends Biotechnol. 2012; 30(10): 546–54. https://doi.org/10.1016/j.tibtech.2012.07.005
[14] Lee SS, Du X, Kim I, Ferguson SJ. Scaffolds for bone-tissue engineering. Matter. 2022; 5(9): 2722–59. https://doi.org/10.1016/j.matt.2022.06.003
[15] Martin I, Wendt D, Heberer M. The role of bioreactors in tissue engineering. Trends Biotechnol. 2004; 22(2): 80–6. https://doi.org/10.1016/j.tibtech.2003.12.001
[16] Hirt C, Papadimitropoulos A, Muraro MG, Mele V, Panopoulos E, Cremonesi E, Ivanek R, Schultz-Thater E, Droeser RA, Mengus C, Heberer M, Oertli D, Iezzi G, Zajac P, Eppenberger-Castori S, Tornillo L, Terracciano L, Martin I, Spagnoli GC. Bioreactor-engineered cancer tissue-like structures mimic phenotypes, gene expression profiles and drug resistance patterns observed “in vivo”. Biomaterials. 2015; 62: 138–46. https://doi.org/10.1016/j.biomaterials.2015.05.037
[17] Friedrich J, Seidel C, Ebner R, Kunz-Schughart LA. Spheroid-based drug screen: considerations and practical approach. Nat Protoc. 2009; 4(3): 309–24. https://doi.org/10.1038/nprot.2008.226
[18] Kim M, Gillies RJ, Rejniak KA. Current Advances in Mathematical Modeling of Anti-Cancer Drug Penetration into Tumor Tissues. Front Oncol. 2013; 3. https://doi.org/10.3389/fonc.2013.00278
[19] El-Kareh AW, Secomb TW. Two-mechanism peak concentration model for cellular pharmacodynamics of Doxorubicin. Neoplasia. 2005; 7(7): 705–13. https://doi.org/10.1593/neo.05118
[20] Januškevičienė I, Petrikaitė V. Exploring doxorubicin transport in 2D and 3D models of MDA-MB-231 sublines: impact of hypoxia and cellular heterogeneity on doxorubicin accumulation in cells. Am J Cancer Res. 2024; 14(7): 3584–99. https://doi.org/10.62347/VNWH9165
[21] Szakács G, Paterson JK, Ludwig JA, Booth-Genthe C, Gottesman MM. Targeting multidrug resistance in cancer. Nat Rev Drug Discov. 2006; 5(3): 219–34. https://doi.org/10.1038/nrd1984
[22] Eliaz RE, Nir S, Marty C, Szoka FC. Determination and modeling of kinetics of cancer cell killing by doxorubicin and doxorubicin encapsulated in targeted liposomes. Cancer Res. 2004; 64(2): 711–8. https://doi.org/10.1158/0008-5472.can-03-0654
[23] Stojkovska J, Zvicer J, Andrejevic M, Janackovic D, Obradovic B, Veljovic DN. Novel composite scaffolds based on alginate and Mg-doped calcium phosphate fillers: Enhanced hydroxyapatite formation under biomimetic conditions. J Biomed Mater Res B Appl Biomater. 2021; 109(12): 2079–90. https://doi.org/10.1002/jbm.b.34856
[24] Stojkovska J, Zvicer J, Milivojevic M, Petrovic I, Stevanovic M, Obradovic B. Validation of a novel perfusion bioreactor system in cancer research. Hem Ind. 2020; 74(3): 187–96. https://doi.org/10.2298/HEMIND200329015S
[25] Gamble M. The Hematoxylins and Eosin. Theory and Practice of Histological Techniques. Elsevier; 2008;121–34. https://doi.org/10.1016/B978-0-443-10279-0.50016-6
[26] Bayen AM., Kong Qingkai, Siauw Timmy. Python programming and numerical methods : a guide for engineers and scientists. Academic Press is an imprint of Elsevier; 2021
[27] Tu B, Zhu J, Liu S, Wang L, Fan Q, Hao Y, Fan C, Tang T-T. Mesenchymal stem cells promote osteosarcoma cell survival and drug resistance through activation of STAT3. Oncotarget. 2016; 7(30): 48296–308. https://doi.org/10.18632/oncotarget.10219
[28] Yang J, Ma Z, Wang Y, Wang Z, Tian Y, Du Y, Bian W, Duan Y, Liu J. Necrosis of osteosarcoma cells induces the production and release of high mobility group box 1 protein. Exp Ther Med. 2017. https://doi.org/10.3892/etm.2017.5415
[29] Abdollahzadeh H, Amoabediny G, Haghiralsadat F, Rahimi F, Adibfar A. Liposomal Doxorubicin Kinetic Study in an In vitro 2D and 3D Tumor Model for Osteosarcoma in a Perfusion Bioreactor. Pharm Nanotechnol. 2023; 11(5): 447–59. https://doi.org/10.2174/2211738511666230501202946
[30] Minchinton AI, Tannock IF. Drug penetration in solid tumours. Nat Rev Cancer. 2006; 6(8): 583–92. https://doi.org/10.1038/nrc1893
[31] Lobo ED, Balthasar JP. Pharmacodynamic modeling of chemotherapeutic effects: Application of a transit compartment model to characterize methotrexate effects in vitro. AAPS PharmSci. 2002; 4(4): 212–22. https://doi.org/10.1208/ps040442